[go: up one dir, main page]

AR109157A1 - Forma de dosificación de liberación controlada resistente a la liberación abrupta de la dosis - Google Patents

Forma de dosificación de liberación controlada resistente a la liberación abrupta de la dosis

Info

Publication number
AR109157A1
AR109157A1 ARP170102099A ARP170102099A AR109157A1 AR 109157 A1 AR109157 A1 AR 109157A1 AR P170102099 A ARP170102099 A AR P170102099A AR P170102099 A ARP170102099 A AR P170102099A AR 109157 A1 AR109157 A1 AR 109157A1
Authority
AR
Argentina
Prior art keywords
release
mph
salt
dosage form
resistant
Prior art date
Application number
ARP170102099A
Other languages
English (en)
Inventor
Ana C Pastini
Joaquina Faour
Guido S Bigatti
Cristian R Franco
Hernan D Benedetti
Original Assignee
Osmotica Kereskedelmi Es Szolgaltato Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Kereskedelmi Es Szolgaltato Kft filed Critical Osmotica Kereskedelmi Es Szolgaltato Kft
Publication of AR109157A1 publication Critical patent/AR109157A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un dispositivo osmótico que comprende metilfenidato (MPH) o una sal del mismo, caracterizado porque exhibe un incremento relacionado con etanol de menos de 1,5 veces en la cantidad total de MPH o una sal del mismo liberada desde el dispositivo durante los primeros 120 minutos cuando se comparan las velocidades de liberación de MPH o una sal del mismo en agua y en etanol 40% en agua. Reivindicación 3: El dispositivo osmótico de acuerdo con las reivindicaciones 1 ó 2 caracterizado porque comprende un núcleo y una membrana semipermeable que encierra el núcleo, en donde el dispositivo osmótico provee una liberación de MPH o una sal del mismo desde el núcleo de acuerdo con el siguiente perfil de liberación cuando el dispositivo osmótico es colocado en etanol 40% en ácido clorhídrico 0,1N a 37 ± 1ºC en un Aparato tipo 7 de la USP @@@@@@@@@
ARP170102099A 2017-02-03 2017-07-26 Forma de dosificación de liberación controlada resistente a la liberación abrupta de la dosis AR109157A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762454269P 2017-02-03 2017-02-03
US15/424,134 US9707217B1 (en) 2017-02-03 2017-02-03 Dose-dumping resistant controlled release dosage form

Publications (1)

Publication Number Publication Date
AR109157A1 true AR109157A1 (es) 2018-10-31

Family

ID=59297927

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102099A AR109157A1 (es) 2017-02-03 2017-07-26 Forma de dosificación de liberación controlada resistente a la liberación abrupta de la dosis

Country Status (5)

Country Link
US (5) US9707217B1 (es)
AR (1) AR109157A1 (es)
CA (1) CA2992767C (es)
CL (1) CL2017001919A1 (es)
UY (1) UY37344A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707217B1 (en) * 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US10350395B2 (en) 2017-06-23 2019-07-16 Cook Medical Technologies Llc Introducer for lumen support or dilation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4036227A (en) 1973-04-25 1977-07-19 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US4135514A (en) 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4874388A (en) 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US4957494A (en) 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4814181A (en) 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US5178866A (en) 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5232705A (en) 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
EP0664118B1 (en) 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
HK1046638B (zh) 1998-06-03 2006-02-24 阿尔扎有限公司 提供药物长效治疗的方法和装置
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
CN104739797A (zh) 2015-03-06 2015-07-01 田武 一种释放速率递增的渗透泵片及其制备方法
US9707217B1 (en) * 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form

Also Published As

Publication number Publication date
CA2992767C (en) 2023-10-17
CL2017001919A1 (es) 2018-03-16
US10695336B2 (en) 2020-06-30
US20180221360A1 (en) 2018-08-09
US9855258B1 (en) 2018-01-02
UY37344A (es) 2017-09-29
CA2992767A1 (en) 2018-08-03
US20190167654A1 (en) 2019-06-06
US9707217B1 (en) 2017-07-18
US9827234B1 (en) 2017-11-28
US10265308B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2020012966A (es) Combinacion, composicion y preparacion de combinacion farmaceutica que comprende activador de glucocinasa e inhibidor de sglt-2, metodos de preparacion y usos de las mismas.
AR109452A1 (es) Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
UY37363A (es) Sulfonilureas y compuestos relacionados y sus usos
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CO6382132A2 (es) Tratamiento de pirfenidona para pacientes con funcion hepatica atipica
MX2022000143A (es) Metodos novedosos.
AR093705A1 (es) Depsipeptido y sus usos
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR103118A1 (es) Tratamientos médicos basados en anamorelina
CY1121141T1 (el) Συνθεση στοματοδιασπειρομενου φιλμ που περιλαμβανει εναλαπριλη για την θεραπεια υπερτασης σε παιδιατρικο πληθυσμο
AR109157A1 (es) Forma de dosificación de liberación controlada resistente a la liberación abrupta de la dosis
MX2019003039A (es) Forma de dosificacion de alivio prolongado.
MX2017005419A (es) Tratamiento o prevencion de anemia en mamiferos no humanos preñados.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2017002818A (es) Composiciones topicas de pterostilbeno para utilizarse en el tratamiento de la perdida inducida por uv de la funcion de barrera en la piel.

Legal Events

Date Code Title Description
FB Suspension of granting procedure